3F8 Antibody Dose Escalation Plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma: A Phase I Trial.
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2013
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Sargramostim
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2013 Planned end date changed from 1 Dec 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.